Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Back

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Not Recruiting

Open to: FEMALE

Age: 18.0 - 130.0

London Cambridge Manchester Oxford

Medical Conditions

Triple Negative Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2018 Nov 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8

Intervention Arm Group : Arm 1;Arm 2;Arm 5;Arm 6;Arm 7;Arm 8;

Intervention Type : DRUG
Intervention Description : Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off

Intervention Arm Group : Arm 2;

Intervention Type : DRUG
Intervention Description : Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1

Intervention Arm Group : Arm 5;

Intervention Type : DRUG
Intervention Description : Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off

Intervention Arm Group : Arm 1;Arm 2;Arm 5;

Intervention Type : DRUG
Intervention Description : Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w

Intervention Arm Group : Arm 6;

Intervention Type : DRUG
Intervention Description : Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w

Intervention Arm Group : Arm 7;Arm 8;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    London
    EC1M 6BQ
  • Research Site
    Cambridge
    CB2 0QQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Oxford
    OX3 7LE


The study is sponsored by AstraZeneca




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03742102
Last updated 15 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top